SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Cerus Corporation (CERS) News

Follow Cerus Corporation (CERS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CERS Asset equity Sector Markets 90 days 9 Last 1.86 Updated Nov 03, 2026, 05:49 AM UTC Open live news feed Open CERS chart & news
M CERS Reports Fiscal Q3 Net Profit of -513万美元 Profit attributable to shareholders was -513万美元, up 61.84% year over year. Basic EPS was -0.03美元. EQUITY | Nov 03, 2026, 05:49 AM UTC L Cerus Reports Q3 EPS of USD 0 EARNINGS | Nov 02, 2026, 09:30 PM UTC M Cerus Blood Safety System Meets Primary Endpoint in Late-Stage Study EQUITY | Nov 02, 2026, 09:29 PM UTC M Cerus Reports Q3 Gross Profit of USD 30.3 Million Cerus reported Q3 adjusted EBITDA of USD 5.7 million, versus an IBES estimate of USD 4 million. EQUITY | Nov 02, 2026, 09:25 PM UTC L Cerus Reports Positive Topline Results From Phase 3 RedeS Trial Cerus announced positive topline results from its Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells. EQUITY | Nov 02, 2026, 09:25 PM UTC M Cerus Q3 Product Revenue Rises 10% to $57.7 Million Cerus reported Q3 2026 product revenue of $57.7 million, up 10% from $52.7 million a year earlier. It reiterated 2026 product revenue guidance of $229 million–$231 million, up 11%–12% from 2025. EQUITY | Nov 02, 2026, 09:22 PM UTC M Cerus Q3 2026 Net Loss Widens to $550,000 EQUITY | Nov 02, 2026, 09:21 PM UTC M Cerus Announces Third-Quarter 2026 Financial Results Cerus said it reported financial results for the quarter ended September 30, 2026, and provided a business update. EQUITY | Nov 02, 2026, 09:06 PM UTC M Cerus’ INTERCEPT for Red Blood Cells Meets Phase 3 Primary Endpoint Cerus said its INTERCEPT system for red blood cells met the primary efficacy endpoint in a Phase 3 study. EQUITY | Nov 02, 2026, 09:03 PM UTC L Freedom initiates CERS at Buy, sets $6.50 price target Freedom initiates coverage of CERS with a Buy rating and a $6.50 price target. EQUITY | Aug 20, 2026, 05:38 PM UTC M Cerus Shares Rise ARK Investment buys 255K shares of Cerus EQUITY | Aug 12, 2026, 12:20 AM UTC H Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 300 points on Friday. Shares of Apple Inc (NASDAQ: AAPL ) fell sharply in pre-market trading after the company posted results for th EARNINGS | Jul 31, 2026, 12:03 PM UTC L CERS Cerus raises 2026 product revenue guidance to $229M-$231M\n CERS Cerus raises 2026 product revenue guidance to $229M-$231M\n EARNINGS | Jul 30, 2026, 08:20 PM UTC L Cerus Raises FY2026 Sales Guidance from $227.000M-$231.000M to $229.000M-$231.000M vs $245.200M Est Cerus (NASDAQ: CERS ) raises FY2026 sales outlook from $227.000 million-$231.000 million to $229.000 million-$231.000 million vs $245.200 million estimate. EARNINGS | Jul 30, 2026, 08:02 PM UTC L CERS Cerus RESULTS: Q2, Q2 gross profit $29.5M, Q2 ADJ EBITDA $3M, Q2 operating expenses $37.3M, Q2 gross margin 51.4% CERS Cerus RESULTS: Q2, Q2 gross profit $29.5M, Q2 ADJ EBITDA $3M, Q2 operating expenses $37.3M, Q2 gross margin 51.4% EARNINGS | Jul 30, 2026, 08:01 PM UTC